phase 1 Search Results


joint movement phase 1  (CH Instruments)
90
CH Instruments joint movement phase 1
Joint Movement Phase 1, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc11000395-4-0-4?v=CH+Instruments
Average 90 stars, based on 1 article reviews
joint movement phase 1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
phase 1 clinical trial nct01375842  (Genentech inc)
90
Genentech inc phase 1 clinical trial nct01375842
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Phase 1 Clinical Trial Nct01375842, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc05838579-109-25-36?v=Genentech+inc
Average 90 stars, based on 1 article reviews
phase 1 clinical trial nct01375842 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
phase 1/2 randomized trial  (Accelagen inc)
90
Accelagen inc phase 1/2 randomized trial
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Phase 1/2 Randomized Trial, supplied by Accelagen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc08216129-117-2-10?v=Accelagen+inc
Average 90 stars, based on 1 article reviews
phase 1/2 randomized trial - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
phase 1/2 a protocol  (Clinilabs)
90
Clinilabs phase 1/2 a protocol
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Phase 1/2 A Protocol, supplied by Clinilabs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pm36456694-2065-1-12?v=Clinilabs
Average 90 stars, based on 1 article reviews
phase 1/2 a protocol - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
sponsored phase 1 research  (The Medicines Company)
90
The Medicines Company sponsored phase 1 research
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Sponsored Phase 1 Research, supplied by The Medicines Company, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pm39327154-115-4-8?v=The+Medicines+Company
Average 90 stars, based on 1 article reviews
sponsored phase 1 research - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
phase 1 trial  (Biotrial Inc)
90
Biotrial Inc phase 1 trial
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Phase 1 Trial, supplied by Biotrial Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc06234706-28-1-10?v=Biotrial+Inc
Average 90 stars, based on 1 article reviews
phase 1 trial - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
acidifying-buffing adjuvant phase1  (Arysta LifeScience Corporation)
90
Arysta LifeScience Corporation acidifying-buffing adjuvant phase1
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Acidifying Buffing Adjuvant Phase1, supplied by Arysta LifeScience Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc06783860-180-15-19?v=Arysta+LifeScience+Corporation
Average 90 stars, based on 1 article reviews
acidifying-buffing adjuvant phase1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
building co.—phase 1  (ProCore Bio Med Ltd)
90
ProCore Bio Med Ltd building co.—phase 1
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Building Co.—Phase 1, supplied by ProCore Bio Med Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/us12118485-177-118-118?v=ProCore+Bio+Med+Ltd
Average 90 stars, based on 1 article reviews
building co.—phase 1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
sinopharm/wibp unnamed phase 1  (Sinopharm ltd)
90
Sinopharm ltd sinopharm/wibp unnamed phase 1
Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial <t>NCT01375842</t> the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.
Sinopharm/Wibp Unnamed Phase 1, supplied by Sinopharm ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc07978427-42-2-0?v=Sinopharm+ltd
Average 90 stars, based on 1 article reviews
sinopharm/wibp unnamed phase 1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
phase 1 nct04064905  (ModernaTX Inc)
90
ModernaTX Inc phase 1 nct04064905
Zika vaccine candidates in clinical trials.
Phase 1 Nct04064905, supplied by ModernaTX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc08566937-8-3-0?v=ModernaTX+Inc
Average 90 stars, based on 1 article reviews
phase 1 nct04064905 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
ald-301 completed phase 1/2 study in critical limb ischemia  (Cytomedix Inc)
90
Cytomedix Inc ald-301 completed phase 1/2 study in critical limb ischemia
Zika vaccine candidates in clinical trials.
Ald 301 Completed Phase 1/2 Study In Critical Limb Ischemia, supplied by Cytomedix Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/pmc08576746-198-48-39?v=Cytomedix+Inc
Average 90 stars, based on 1 article reviews
ald-301 completed phase 1/2 study in critical limb ischemia - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
phase 1/2 trials  (Gennova Inc)
90
Gennova Inc phase 1/2 trials
Zika vaccine candidates in clinical trials.
Phase 1/2 Trials, supplied by Gennova Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phase+1/10__1016_slash_j__onano__2022__100078-154-16-28?v=Gennova+Inc
Average 90 stars, based on 1 article reviews
phase 1/2 trials - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial NCT01375842 the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.

Journal: JAMA Oncology

Article Title: Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

doi: 10.1001/jamaoncol.2017.3064

Figure Lengend Snippet: Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial NCT01375842 the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.

Article Snippet: Given that this agent was recently approved, and there are few clinical trials available, we used unpublished data on phase 1 clinical trial ( {"type":"clinical-trial","attrs":{"text":"NCT01375842","term_id":"NCT01375842"}} NCT01375842 ) that was provided to us by the study sponsor (Genentech Inc).

Techniques:

Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial NCT01375842 the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.

Journal: JAMA Oncology

Article Title: Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

doi: 10.1001/jamaoncol.2017.3064

Figure Lengend Snippet: Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. For the phase 1 clinical trial NCT01375842 the study sponsor (Genentech Inc) provided data (unpublished). Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; and RE MODEL, random effects model.

Article Snippet: Given that this agent was recently approved, and there are few clinical trials available, we used unpublished data on phase 1 clinical trial ( {"type":"clinical-trial","attrs":{"text":"NCT01375842","term_id":"NCT01375842"}} NCT01375842 ) that was provided to us by the study sponsor (Genentech Inc).

Techniques:

Zika vaccine candidates in clinical trials.

Journal: Frontiers in Immunology

Article Title: Hide and Seek: The Interplay Between Zika Virus and the Host Immune Response

doi: 10.3389/fimmu.2021.750365

Figure Lengend Snippet: Zika vaccine candidates in clinical trials.

Article Snippet: ModernaTX, Inc. , Phase 1 NCT04064905 (Completed) , Not reported , .

Techniques: Vaccines, Binding Assay, Produced, Purification, Virus, Immunopeptidomics